Litigation Details for Almirall LLC v. Taro Pharmaceutical Industries Ltd. (D. Del. 2017)

Almirall LLC v. Taro Pharmaceutical Industries Ltd. (D. Del. 2017)

Docket		Date Filed	2017-06-01
Court	District Court, D. Delaware	Date Terminated	2019-03-11
Cause	35:271 Patent Infringement	Assigned To	Joseph F. Bataillon
Jury Demand	None	Referred To	Sherry R. Fallon
Parties	ALMIRALL LLC
Patents	8,778,365; 9,517,219
Attorneys	Anthony David Raucci
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Almirall LLC v. Taro Pharmaceutical Industries Ltd. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-06-01				External link to document
2017-06-01	113		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,517,219 B2 . (Blumenfeld, Jack…2017 11 March 2019 1:17-cv-00663 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2017-06-01	137		would induce infringement of U.S. Patent No. 9,517,219 (“the ’219 patent”) under the doctrine of equivalents…asserted claims are invalid. The ’219 patent is a method patent. The matter is set for trial on February…since the language of the asserted patent claims, and not the patent holder’s commercial product, to define… that during the prosecution of the ’219 patent, the patent examiner defined a POSA as having a level… a POSA for the ’219 patent. Taro proposes: A POSA for the ’219 patent would have had at least	External link to document
2017-06-01	34		424/400 Patent Number: 8,778,365 First Named Bhushan Hardas…prosecution of any patent application before the USPTO or any corresponding foreign patent authority that…partes review) before the USPTO on any patent-in- suit or any patent issued from any application that (…prosecute any patent application before the USPTO or any corresponding foreign patent authority that…prosecution of any patent application before the USPTO or any corresponding foreign patent authority that	External link to document
2017-06-01	39		infringement of United States Patent No. 9,517,219 ("the '219 patent"), which is entitled …;Allergan") brought this civil action for patent infringement under the Hatch-Waxman Act on June…for Use Thereof. (D.I. 1 at if 18) The '219 patent encompasses the approved use of Allergan's…prosecution of the application leading to the '219 patent, which allegedly limited the claimed polymeric…multi-component PVB and the claimed PVB in the '219 patent is the proper subject of fact and expert discovery	External link to document
2017-06-01	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,517,219 B2. (nmg) (Entered:…2017 11 March 2019 1:17-cv-00663 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2017-06-01	87	Report and Recommendations	alleges infringement of U.S. Patent No. 9,517,219 ("the '219 patent") under the doctrine …x27;219 patent. However, Allergan alleges that Taro's product infringes the '219 patent through…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which the…the '219 patent claims a PVB "comprising [A/SA] copolymer." ('219 patent, col. 16:8-… 7 '219 patent over the prior art by explaining that the '219 patent employs an A/SA copolymer	External link to document

Litigation Summary and Analysis for Almirall LLC v. Taro Pharmaceutical Industries Ltd.| 1:17-cv-00663

Last updated: February 4, 2026

Overview

The case involves patent litigation between Almirall LLC and Taro Pharmaceutical Industries Ltd., filed in the District of Delaware. The complaint was initiated in 2017, focusing on allegations of patent infringement concerning dermatological drugs.

Background and Patent Specification

Almirall LLC holds U.S. Patent No. 8,691,000, issued in 2014, relating to a specific formulation of topical pharmaceuticals involving a corticosteroid compound. The patent claims cover a stabilized, bioequivalent formulation suitable for treating skin conditions such as psoriasis and eczema.

Taro Pharmaceutical, a generic manufacturer, sought FDA approval to market a generic version of the branded drug, prompting Almirall to file suit for patent infringement under 35 U.S.C. § 271.

Claims and Allegations

Almirall claims Taro's proposed generic infringes all asserted claims of the '000 patent by manufacturing a topical corticosteroid formulation that falls within the scope of the patent's claims. The allegations include direct infringement, contributory infringement, and inducement to infringe.

Procedural Developments

• Initial Complaint (2017): Almirall sued Taro for patent infringement, seeking injunctive relief and damages.
• Markman Hearing (2018): The court inquired into claim constructions, focusing on terms like "stabilized formulation" and "bioequivalent."
• Summary Judgment Motions (2019): Taro moved to dismiss based on non-infringement and invalidity arguments.
• Trials and Rulings: The case was scheduled for trial in 2020 but was stayed due to settlement discussions, which later fell through.

Key Legal Issues

• Claim Construction: The court interpreted "stabilized formulation" as requiring specific chemical stability parameters, impacting infringement analysis.
• Invalidity: Taro argued the patent lacked novelty and was obvious in light of prior art, notably referencing U.S. Patent No. 7,922,328.
• Infringement: The core issue was whether Taro’s formulation embodied all elements as construed by the court.

Recent Developments

In late 2021, the case remained pending due to ongoing disputes over claim validity and infringement scope. There have been no publicly available judgments or rulings post-2019.

Legal Significance and Industry Impact

This litigation exemplifies the strategic use of patent rights in the dermatology segment, where formulation patents provide substantial protection. The dispute illustrates the importance of precise claim language and the influence of prior art on patent validity.

For generic firms like Taro, patent challenges revolve around invalidity defenses, whereas brand holders like Almirall focus on enforcement to protect market share.

Market and Business Implications

Litigation outcomes impact drug exclusivity and pricing. Successful infringement claims can prevent generic entry, maintaining higher drug prices. Conversely, invalidation or invalidity defenses facilitate generic market entry, leading to significant price reductions.

Conclusion

As of the current date, the case remains unresolved. Both parties continue to assess their positions, with ongoing focus on claim interpretation and validity challenges.

---

Key Takeaways

• The case underscores the significance of patent claim language precision.
• Validity defenses rely heavily on prior art analysis, especially for formulation patents.
• Settlement negotiations in patent litigation can span years without resolution.
• Patent disputes impact generic market entry, pricing, and drug availability.
• The outcome could influence future litigation strategies in dermatological drug patents.

---

FAQs

1. What is the main patent involved in this case?
U.S. Patent No. 8,691,000, related to a stabilized topical corticosteroid formulation.

2. Why did Taro Pharmaceutical challenge the patent?
Taro argued the patent was invalid due to lack of novelty and obviousness based on prior art references.

3. How does claim construction affect the case?
Interpreting terms like "stabilized formulation" influences whether Taro's generic formulation infringes the patent.

4. What legal strategies are common in such patent disputes?
Plaintiffs focus on infringement and validity, while defendants challenge the patent's scope and prior art validity.

5. When might a resolution occur?
No court decision has been issued since 2019; resolution timing depends on settlement, trial schedules, or appeals.

---

Sources

[1] Court Docket No. 1:17-cv-00663, District of Delaware
[2] Almirall LLC v. Taro Pharmaceutical Industries Ltd., Complaint, 2017
[3] Patent No. 8,691,000, U.S. Patent and Trademark Office
[4] Public filings from the District of Delaware (2018–2021)